Burden of musculoskeletal disorders in Iran during 1990-2017: estimates from the Global Burden of Disease Study 2017.


Journal

Archives of osteoporosis
ISSN: 1862-3514
Titre abrégé: Arch Osteoporos
Pays: England
ID NLM: 101318988

Informations de publication

Date de publication:
10 07 2020
Historique:
received: 11 03 2020
accepted: 04 06 2020
entrez: 12 7 2020
pubmed: 12 7 2020
medline: 1 12 2020
Statut: epublish

Résumé

Musculoskeletal diseases (MSDs) are the leading cause of disability and facing them demands updated reports on their burden for efficient policymaking. We showed Iran had the highest female-to-male ratio and highest increase in the burden of musculoskeletal diseases, in the past three decades, worldwide. We further confirmed the role of population aging as the main cause. MSDs comprise most of the top causes of years lived with disability (YLDs) worldwide and are rapidly increasing in lower- and middle-income countries. Here, we present disability and mortality due to MSDs in Iran at the national level from 1990 to 2017. We used Global Burden of Disease (GBD) 2017 Study data and standard methodology and presented the burden of MSDs in rates of years of life lost (YLLs), YLDs, and disability-adjusted life years (DALYs) during 1990-2017, for population aged ≥ 5 years old. We further explored attributable risk factors and decomposed the changing trend in DALYs to assess underlying causes. In Iran, MSDs were responsible for 1.82 million (95%uncertainty interval [UI] 1.3-2.4) DALYs, in 2017. During the past 28 years, with 1.75% annualized percentage change (APC), Iran had the highest percentage increase in the all-ages MSD DALYs rate worldwide, while the age-standardized DALYs APC was negligible. Low back pain was the greatest contributor to DALYs and caused 4.5% of total DALYs. The female population is experiencing considerably higher burden of MSDs, with 115% and 48% higher all-ages YLLs and YLDs rates per 100,000, respectively (YLLs 28.7; YLDs 2629.1), than males (YLLs 13.2; YLDs 1766.1). However, due to wide UIs, difference was not significant. Only 17.6% of MSD YLDs are attributable to assessed risk factors. Despite that MSDs are rising as an important cause of disability in Iran, these conditions are not sufficiently addressed in health policies. There is urgent need for cross-sectoral engagement, especially addressing the MSDs in females.

Identifiants

pubmed: 32651719
doi: 10.1007/s11657-020-00767-8
pii: 10.1007/s11657-020-00767-8
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103

Auteurs

M Shahrezaee (M)

Department of Orthopedic Surgery, AJA University of Medical Sciences, Tehran, Iran.

S Keshtkari (S)

Department of Internal Medicine, AJA University of Medical Sciences, Tehran, Iran.

M Moradi-Lakeh (M)

Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran.

M Abbasifard (M)

Department of Internal Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Clinical Research Development Unit, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

V Alipour (V)

Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
Department of Health Economics, Iran University of Medical Sciences, Tehran, Iran.

S Amini (S)

Department of Health Services Management, Arak University of Medical Sciences, Arak, Iran.

J Arabloo (J)

Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.

A Arzani (A)

Center for Non-Communicable Pediatric Diseases, Health Research Institute, School of Nursing and Midwifery, Babol University of Medical Sciences, Babol, Iran.

M Bakhshaei (M)

Department of Anesthesiology, Hamedan University of Medical Sciences, Hamadan, Iran.

A Barzegar (A)

Department of Occupational Health Engineering, Kermanshah University of Medical Sciences, Kermanshah, Iran.

A Bijani (A)

Social Determinants of Health Research Center, Babol University of Medical Sciences, Babol, Iran.

M Dianatinasab (M)

Department of Epidemiology, Shahroud University of Medical Sciences, Shahroud, Iran.
Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran.

S Eskandarieh (S)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

R Ghanei Gheshlagh (RG)

Faculty of Nursing and Midwifery, Kurdistan University of Medical Sciences, Sanandaj, Iran.

A Ghashghaee (A)

Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
Student Research Committee, Iran University of Medical Sciences, Tehran, Iran.

R Heidari-Soureshjani (R)

School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.

S S N Irvani (SSN)

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

A Lahimchi (A)

First Faculty of Medicine, Charles University, Prague, Czech Republic.

S Maleki (S)

Clinical Research Development Center, Taleghani and Imam Ali Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.

N Manafi (N)

Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Department of Ophthalmology, Iran University of Medical Sciences, Tehran, Iran.

A Manafi (A)

Department of Plastic Surgery, Iran University of Medical Sciences, Tehran, Iran.

M A Mansournia (MA)

Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.

A Mohammadian-Hafshejani (A)

Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran.

M A Mohseni Bandpei (MAM)

Pediatric Neurorehabilitation Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

R Moradzadeh (R)

Department of Epidemiology, Arak University of Medical Sciences, Arak, Iran.

M Naderi (M)

Clinical Research Development Center, Taleghani and Imam Ali Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.

K Pakshir (K)

Department of Parasitology and Mycology, Shiraz University of Medical Sciences, Shiraz, Iran.

A Rafiei (A)

Department of Immunology, Mazandaran University of Medical Sciences, Sari, Iran.
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

V Rashedi (V)

School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Iran University of Medical Sciences, Tehran, Iran.

N Rezaei (N)

Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

A Rezapour (A)

Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.

M A Sahraian (MA)

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

S Shahabi (S)

Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

M Shamsi (M)

School of Rehabilitation Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.

A Soheili (A)

Nursing Care Research Center, Semnan University of Medical Sciences, Semnan, Iran.

A Soroush (A)

School of Rehabilitation Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.

M Zamani (M)

Student Research Committee, Babol University of Medical Sciences, Babol, Iran.

B Mohajer (B)

Department of Orthopedic Surgery, AJA University of Medical Sciences, Tehran, Iran. b.mohajer@ncdrc.info.

F Farzadfar (F)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. f-farzadfar@tums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH